TrendPeek
Business

What Happened to soleno therapeutics?

Overview

Soleno Therapeutics is trending because Neurocrine Biosciences has announced its intention to acquire the company for approximately $2.9 billion. This acquisition aims to bolster Neurocrine's portfolio in endocrinology and rare diseases, particularly focusing on Soleno's promising obesity disorder treatment.

What the News Says

1

Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

PR Newswire
2

Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment

Financial Times
3

Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal

STAT

Get the full breakdown — why it matters, background context, and what comes next.

Read Full Analysis